All questionsPharmacology: Kesimpta (ofatumumab) in relapsing multiple sclerosis7 questions · 2 sourcesMechanismHow does Kesimpta work (mechanism of action)?“The precise mechanism by which ofatumumab exerts its therapeutic effects in multiple sclerosis is unknown, but is presumed to involve binding to CD20, a cell surface antigen present on pre-B and mature B lymphocytes. Following cell surface binding to B lymphocytes, ofatumumab results in antibody-dependent cellular cytolysis and complement-mediated lysis.” (opens the source at this quote in a new tab)CopyFlag“KESIMPTA is thought to work by selectively binding to sites on both the small and large extracellular loops of CD20.4” (opens the source at this quote in a new tab)CopyFlag“KESIMPTA causes CD20+ B cells to be vulnerable to both immediate and delayed B-cell lysis by mechanisms such as complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity4” (opens the source at this quote in a new tab)CopyFlagHow quickly does Kesimpta deplete B cells?“For B-cell counts, assays for CD19+ B-cells are used because the presence of ofatumumab interferes with the CD20 assay. In Study 1 and Study 2, KESIMPTA administered as recommended, resulted in a reduction of CD19+ B-cells to below the LLN in 77.0% and 78.8% of patients, respectively, one week after treatment initiation, and in 95.0% and 95.8% of patients, respectively, two weeks after treatment initiation [see Dosage and Administration (2.2) and Clinical Studies (14)]. In Study 1 and Study 2, at Week 12, 99.3% to 99.5% of patients had CD19+ B-cell counts below LLN. The CD19+ B-cell counts remained below LLN for approximately 97% of patients in Study 1 and 92% of patients in Study 2 from 12 weeks through 120 weeks while on KESIMPTA treatment.” (opens the source at this quote in a new tab)CopyFlagHow long after stopping Kesimpta do B cells recover?“Data from Studies 1 and 2 indicate a median time to B-cell recovery to either LLN or baseline value of 24.6 weeks post- treatment discontinuation. Pharmacokinetics and pharmacodynamics modeling and simulation for B-cell repletion corroborate these data, predicting median time to B-cell recovery to LLN of 23 weeks post-treatment discontinuation.” (opens the source at this quote in a new tab)CopyFlagPharmacokineticsHow long does Kesimpta stay in your system (half-life)?“Ofatumumab is eliminated by both linear catabolic pathways and a non-linear B-cell mediated pathway, resulting in non- constant elimination half-life. Initially, a higher baseline B-cell count results in greater B-cell-mediated elimination and shorter ofatumumab half-life. As the B-cells are depleted, the catabolic pathway predominates, resulting in a relatively longer ofatumumab half-life compared to earlier in therapy when both elimination pathways were available. Following B- cell depletion, clearance was estimated to be 0.34 L/day following repeated subcutaneous administration of KESIMPTA 20 mg injections. The half-life at steady state was estimated to be approximately 16 days following subcutaneous administration of repeated KESIMPTA 20 mg dosage.” (opens the source at this quote in a new tab)CopyFlagHow is Kesimpta metabolized and eliminated?“Ofatumumab is a protein for which the expected metabolic pathway is degradation to small peptides and amino acids by ubiquitous proteolytic enzymes.” (opens the source at this quote in a new tab)CopyFlag“Ofatumumab, a monoclonal antibody, is not likely to undergo renal excretion.” (opens the source at this quote in a new tab)CopyFlagHow is Kesimpta absorbed after subcutaneous injection?“A subcutaneous dose of 20 mg every 4 weeks leads to a mean AUCtau of 483 mcg h/mL and a mean Cmax of 1.43 mcg/mL at steady state. After subcutaneous administration, ofatumumab is believed to be predominantly absorbed via the lymphatic system similarly to other therapeutic monoclonal antibodies.” (opens the source at this quote in a new tab)CopyFlagComponentsWhat are the inactive ingredients in Kesimpta?“Each 20 mg/0.4 mL KESIMPTA Sensoready Pen or prefilled syringe delivers 0.4 mL of solution. Each 0.4 mL contains 20 mg of ofatumumab, and arginine (4 mg), disodium edetate (0.007 mg), polysorbate 80 (0.08 mg), sodium acetate” (opens the source at this quote in a new tab)CopyFlag“trihydrate (2.722 mg), sodium chloride (1.192 mg), and Water for Injection, USP with a pH of 5.5. Hydrochloric acid may have been added to adjust pH.” (opens the source at this quote in a new tab)CopyFlag